Browse studies

Find your next paid study

5 recruiting studies matching your filters

An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors.

This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 al…

Diffuse Astrocytoma, IDH-MutantGlioblastoma, IDH-wildtypeBrain Metastases, Adult+18 more

Estimated

~$10 – $8,750

Neonc Technologies, Inc.NCT06047379

Phase 2

Phase II Trial of Treatment Intensification for IDH Wildtype, Non-Histological Glioblastoma, Gliomas (IDH Wildtype Lower Grade Glioma Treatment Intensification)

This phase II trial studies how well temozolomide and radiation therapy work in treating patients with IDH wildtype historically lower grade gliomas or non-his…

Anaplastic Astrocytoma, IDH-WildtypeAnaplastic OligoastrocytomaAnaplastic Oligodendroglioma+6 more

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT04623931

Phase 1

Phase I/IIa Trial of Retifanlimab and Difluoromethylornithine (DFMO) in Patients With Progressive High-Grade Glioma

This phase I/II trial tests the safety, side effects best dose and effect of retifanlimab with or without difluoromethylornithine (DFMO) for the treatment of h…

Anaplastic OligodendrogliomaAstrocytoma, IDH-Mutant, Grade 3Astrocytoma, IDH-Mutant, Grade 4+3 more

Estimated

~$10 – $6,250

Mayo ClinicNCT07468136

Phase 1

LU-TARGET: A Phase 1 Study of Lutetium-177-PSMA-617 Adjuvant Radiotherapy for IDH Wild Type Gliomas Expressing PSMA Following Standard Treatment

The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type…

GliomaDiffuse Astrocytoma, IDH-Wildtype (Grade 2-4)Glioblastoma, IDH-wildtype+3 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT07223034

Phase 1

A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the max…

Central Nervous System NeoplasmsGlioblastomaGliosarcoma, Adult+20 more

Estimated

~$10 – $8,750

Jazz Pharmaceuticals